Travere Therapeutics' Cash from Discontinued Operations fell 16.21% to -$7.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$7.5 million, marking a year-over-year decrease of 116.44%. This contributed to the annual value of -$7.5 million for FY2024, which is 116.44% down from last year.
Latest data reveals that Travere Therapeutics reported Cash from Discontinued Operations of -$7.5 million as of FY2024, which was down 116.44% from $45.3 million recorded in FY2023.
In the past 5 years, Travere Therapeutics' Cash from Discontinued Operations ranged from a high of $74.6 million in FY2022 and a low of -$7.5 million during FY2024.
Over the past 3 years, Travere Therapeutics' median Cash from Discontinued Operations value was $45.3 million (recorded in 2023), while the average stood at $37.5 million.
Per our database at Business Quant, Travere Therapeutics' Cash from Discontinued Operations climbed by 21.33% in 2022 and then crashed by 116.44% in 2024.
Yearly analysis of 4 years shows Travere Therapeutics' Cash from Discontinued Operations stood at $61.4 million in 2021, then rose by 21.33% to $74.6 million in 2022, then plummeted by 39.19% to $45.3 million in 2023, then tumbled by 116.44% to -$7.5 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value